Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Receives Average Recommendation of “Strong Buy” from Brokerages

Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus price objective of $10.00 for the company and are predicting that the company will post ($0.01) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Kitov Pharmaceuticals an industry rank of 175 out of 265 based on the ratings given to its competitors.

Separately, HC Wainwright raised shares of Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Tuesday, November 21st.

Shares of Kitov Pharmaceuticals (NASDAQ:KTOV) opened at $2.34 on Monday. Kitov Pharmaceuticals has a one year low of $1.27 and a one year high of $3.44.

COPYRIGHT VIOLATION WARNING: “Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Receives Average Recommendation of “Strong Buy” from Brokerages” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at

Kitov Pharmaceuticals Company Profile

Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Get a free copy of the Zacks research report on Kitov Pharmaceuticals (KTOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply